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Second-generation large-diameter head (LDH) MoM THA 
and HRA gained popularity at the beginning of the 21st cen-
tury (FAR, AOANJRR 2016, NJR 2016). Metal particles 
emanate as a result of corrosion and wear of metal-on-metal 
(MoM) hip implants and can disseminate throughout the 
body. These particles can be found in several organs includ-
ing lymphatic tissue, bone marrow, liver, and spleen (Case et 
al. 1994, Shea et al. 1997, Urban et al. 2000, Shimmin and 
Back 2005). Metal debris from hip implants has been associ-
ated with chromosomal aberrations and DNA damage (Case 
et al. 1996, Bonassi et al. 2000, Daley et al. 2004, Polyzois et 
al. 2012, Sarhadi et al. 2015). Wear particles are released both 
from MoM and conventional metal-on-polyethylene (MoP) 
bearings and from the trunnion of MoM THA (Pastides et al. 
2013). However, the risk of cancer was not increased after 
conventional MoP THA or after earlier used first-generation 
MoM THA (Visuri et al. 1996, 2010). 
Previous studies have found no increase in the overall risk 
of cancer after second-generation MoM hip arthroplasty in the 
short term when compared with other bearing types (Mäkelä 
et al. 2012, Smith et al. 2012, Brewster et al. 2013, Lalmo-
hamed et al. 2013). However, follow-up time in these studies 
is relatively short as cancer takes years to develop. A recent 
meta-analysis could not find causative relationship between 
second-generation MoM implants and cancer risk (Chris-
tian et al. 2014). At the same time, a previous Finnish study 
reported an increased incidence of basalioma and soft tissue 
sarcoma in patients treated with MoM implants compared 
with patients treated with non-MoM implants (Mäkelä et al. 
2014). Sarcoma is a severe, life-threatening disease and due to 
these earlier findings we felt obligated to update our data with 
longer follow-up.
Background and purpose — Metal-on-metal (MoM) 
total hip arthroplasty (THA) and hip resurfacing arthroplasty 
(HRA) have been widely used during the early 21st century. 
We assessed the midterm risk of cancer of patients treated 
with modern MoM hip implants compared with patients with 
non-MoM hip implants and the general Finnish population 
with special interest in soft tissue sarcomas and basalioma 
due to the findings of our previous report.
Patients and methods — All large-diameter head MoM 
THAs and hip resurfacings performed in Finland between 
2001 and 2010 were extracted from the Finnish Arthroplasty 
Register (10,728 patients). Patients who underwent conven-
tional THA formed the non-MoM reference cohort (18,235 
patients). Data on cancer cases up to 2014 were extracted 
from the Finnish Cancer Registry. The relative risk of 
cancer in the general population was expressed as the ratio 
of observed to expected number of cases, i.e., standardized 
incidence ratio (SIR). Poisson regression analysis was used 
to compare the cancer risk between the cohorts. The mean 
follow-up was 7.4 years (1–14) in the MoM cohort and 8.4 
years (1–14) in the non-MoM cohort.
Results — The overall risk of cancer in the MoM cohort 
was comparable to the general Finnish population (SIR 0.9, 
95% CI 0.9–1.0). Risk of basalioma in the MoM cohort was 
higher than in the general Finnish population (SIR 1.2, CI 
1.1–1.4) and higher than in the non-MoM cohort in the strati-
fied regression analysis (RR 1.2, CI 1.0–1.4, p = 0.02). The 
SIR of soft-tissue sarcoma in the MoM cohort was 1.4 (CI 
0.6–2.8); the incidence was same as in the non-MoM cohort.
Interpretation — Metal-on-metal hip implants are not 
associated with an increased overall risk of cancer during 
midterm follow-up.
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We have now updated our earlier results on risk of cancer 
(Mäkelä et al. 2012, 2014) in patients treated with primary 
MoM hip implants compared with patients treated with pri-
mary non-MoM THAs and the general Finnish population in 
midterm follow-up, specifically the risk of sarcoma, basali-
oma, and skin melanoma.
Patients and methods
In Finland virtually all cancer cases are recorded in the pop-
ulation-based Finnish Cancer Registry (Teppo et al. 1994, 
Pukkala et al. 2018) and 98% of primary total hip implants 
are recorded in the Finnish Arthroplasty Register (FAR). LDH 
MoM THAs and hip HRAs performed in Finland between 
2001 and 2010 were extracted from the FAR and formed the 
MoM cohort. Patients who underwent metal-on-polyethylene, 
ceramic-on-polyethylene, or ceramic-on-ceramic THA during 
the study period formed the non-MoM reference cohort. All 
of these study subjects were followed-up until December 
31, 2014 for emigration and vital status via the Population 
Registry, and for cancer incidence via Finnish Cancer Reg-
istry through a personal identity code. None of the patients 
were lost to follow-up. While forming the study population 
we included the first hip implant in every patient. If a patient 
received another hip implant later, only those who had similar 
bearings in both sides were included. 
There were 10,728 patients in the MoM cohort and 18,235 
patients in the non-MoM THA cohort included in this study; 
46% of the patients were men (Tables 1 and 2). The number 
of person-years at follow up was 79,521 for the MoM cohort 
and 152,358 for the non-MoM cohort. Of all our patients 497 
(4.6%) had bilateral MoM implants. The mean follow-up was 
7.4 years (0–14) in the MoM cohort and 8.4 years (0–14) in 
the non-MoM cohort. 
Statistics
For both cohorts (MoM and non-MoM) the person-years 
at risk were calculated within stratification of sex, calendar 
period (2001–05 and 2006–10), 5-year age groups, and fol-
low-up time (< 2, 2–5, and > 5 years since the operation). 
The expected number of each type of cancer within each 
stratum was calculated by multiplying the person-years in 
the stratum by the stratum’s age, sex, and calendar-period-
specific cancer incidence rate for the Finnish population. 
The total expected numbers of cancers were summed over 
the strata. The cancer risk relative to the Finnish population, 
i.e., standardized incidence ratio (SIR), was expressed as the 
ratio of observed to expected number of cases. For the 95% 
confidence intervals (CI), we assumed that the number of 
observed cases followed a Poisson distribution. The study 
population and detailed information on the implant types 
have been presented in detail in earlier publications (Mäkelä 
et al. 2012, 2014). 
Poisson regression analysis was used to estimate the relative 
cancer risk between the MoM and non-MoM cohorts for soft 
tissue sarcomas, melanoma and basalioma. Soft-tissue sarcoma 
and basalioma were chosen for Poisson regression due to the 
earlier results of Mäkelä et al. (2012, 2014) and skin melanoma 
due to earlier results with conventional THA (Visuri et al. 2003, 
Onega et al. 2006). The risk estimate (incidence rate ratio) was 
Table 1.  Number of patients (n) according to age at operation, and number of person-years (PY) according to the age at follow-up. The 
non-metal-on-metal cohort consisted of implants with metal-on-polyethylene, ceramic-on-polyethylene, and ceramic-on-ceramic bearing 
surfaces 
 Metal-on-metal cohort Non-metal-on-metal cohort Total
 Men Women Men Women Men Women
Age n PY n PY n PY n PY n PY n PY
  0–9 1 1 – – – – – – 1 1 - -
10–19 5 16 3 16 – – – – 5 16 3 16
20–29 25 136 16 69 4 17 7 29 29 153 23 98
30–39 159 558 67 309 30 119 20 116 189 677 87 425
40–49 741 3,746 471 2,078 143 730 157 578 884 4,476 628 2656
50–59 2,277 11,787 1,643 8,578 850 3,880 922 4,416 3,127 15,667 2,565 12,994
60–69 2,257 19,652 1,581 14,090 2,260 13,980 2,739 16,099 4,517 33,632 4,320 30,189
70–79 763 9,403 594 6,773 3,044 25,854 5,397 39,047 3,807 35,257 5,991 45,820
80– 65 1,276 48 1,036 698 13,610 1,953 33,884 763 14,886 2,001 34,920
Total 6,293 46,573 4,423 32,948 7,029 58,190 11,195 94,168 13,322 104,763 15,618 127,116
PY: person-years
Table 2. Baseline characteristics  for the metal-on-metal cohort and 
for the non-metal-on-metal cohort
 Metal-on- Non-metal-on-
Factor metal cohort metal cohort
Mean age (SD)      59 (10)        71 (9)
Number of women, n (%) 4,426 (41) 11,202 (61)
Primary osteoarthritis, n (%) 9,901 (92) 17,683 (97)
Secondary osteoarthritis, n (%)    827 (8)      552 (3)
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adjusted for age (0–49,50–59, 60–69, 70–79, 80+) and follow-
up time (< 2, 2–5, and > 5 years since the operation). Poisson 
regression analysis was checked for over-dispersion. The level 
of statistical significance was set at p < 0.05. 
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Results
The overall risk of cancer in patients treated with MoM hip 
implants was slightly lower than in the general Finnish popu-
lation (SIR 0.9, 95% CI 0.9–1.0) (Table 3). 
There were 8 soft-tissue sarcomas in the MoM cohort during 
the follow-up period (SIR 1.4, CI 0.6–2.8) (Table 2). The risk 
of soft-tissue sarcoma in the MoM cohort was the same than 
that in the non-MoM cohort (RR 0.9, CI 0.4–2.0, p = 0.8). 
Incidence of basalioma in the MoM cohort was higher than 
in the general Finnish population (SIR 1.2, CI 1.1–1.4; p < 
0.001) (Table 3) and also higher than that of the non-MoM 
cohort (RR 1.2, CI 1.0–1.4, p = 0.02). 
The SIR of skin melanoma in the MoM cohort was 1.1 (CI 
0.8–1.5) and that in the non-MoM cohort was 1.2 (CI 1.0–
1.5) (Table 3). Risk of melanoma in the MoM cohort was not 
higher than that in the non-MoM cohort (RR 0.9, CI 0.6–1.4, 
p = 0.7).
Discussion
We found that the overall midterm risk of cancer was not 
increased in patients treated with MoM hip implants when 
compared wit the general Finnish population in midterm 
follow-up. This is in line with previous short term follow-up 
studies on second-generation MoM hip implants (Mäkelä et 
al. 2012, Smith et al. 2012, Brewster et al. 2013, Lalmohamed 
et al. 2013, Mäkelä  et al. 2014).  The slightly lower overall 
risk of cancer in the MoM group can be influenced by the fact 
that MoM patients tend to be young and possibly healthier 
than the average population, which might cause some selec-
tion bias. A recent study from Slovenia including only THAs 
found a slightly higher risk of overall cancer in patients treated 
with MoM bearing when compared with the general popula-
tion or the non-MoM patients (Levasic et al. 2018). In that 
study the specific cancer types that had higher prevalence in 
the MoM cohort compared with the general population were 
skin cancers excluding melanoma and prostate cancer. Com-
parably, we found higher risk for basalioma in our MoM 
cohort. This confirmation of our results from another country 
is an interesting finding, and needs further research. The study 
cohort size in the study by Levasic et al. was smaller than ours 
(338 MoM THAs). Prostate cancer risk was not increased in 
the MoM cohort in our study when compared with the general 
Finnish population.  
Although MoM hip implants are associated with local pseu-
dotumors, adverse local tissue reactions (ALTR), and possible 
genetic alterations, based on earlier literature it seems that the 
Table 3. Observed numbers of cancer cases, the expected numbers of cancer cases approximated from the Finnish pop-
ulation, and standardized incidence ratios with 95% confidence intervals—according to site—are given for the metal-on-
metal cohort and for the non-metal-on-metal cohort. The latter cohort consisted of implants with metal-on-polyethylene, 
ceramic-on-polyethylene, and ceramic-on-ceramic bearing surfaces
 
 Metal-on-metal cohort Non-metal-on-metal cohort 
Primary site Obs Exp SIR 95% CI % of cancer Obs Exp SIR 95% CI % of cancer
All sites 915 973 0.9 0.9–1.0 9 2851 2852 1.0 1.0–1.0 16
Stomach  23 21 1.1 0.7–1.7 0.2 75 74 1.0 0.8–1.3 0.4
Colon  48 55 0.87 0.6–1.2 0.4 187 199 0.9 0.8–1.1 1
Lung 61 95 0.64 0.5–0.8 a 0.6 203 260 0.78 0.7–0.9 a 1
Corpus uteri 24 22 1.1 0.7–1.6 0.2 78 82 1.0 0.8–1.2 0.4
Prostate 239 216 1.1 1.0–1.2 2 478 461 1.0 1.0–1.1 3
Kidney 31 29 1.1 0.7–1.5 0.3 83 82 1.0 0.8–1.2 0.5
Bladder 32 41 0.8 0.5–1.1 0.3 131 128 1.0 0.9–1.2 0.7
Soft-tissue sarcoma 8 6 1.4 0.6–2.8 0.07 20 17 1.2 0.7–1.8 0.1
Non-Hodgkin lymphoma 37 38 1.0 0.7–1.4 0.3 118 108 1.1 0.9–1.3 0.7
Hodgkin lymphoma 2 2 0.9 0.1–3.1 0.02 3 4 0.7 0.1–2.0 0.02
Multiple myeloma 13 12 1.1 0.6–1.8 0.1 36 41 0.9 0.6–1.2 0.2
Leukemia 17 18 1.0 0.6–1.5 0.2 60 58 1.0 0.8–1.3 0.3
Melanoma 38 36 1.1 0.8–1.5 0.4 105 87 1.2 1.0–1.5 0.6
Basalioma 306 246 1.2 1.1–1.4 a 3 913 878 1.0 1.0–1.1 5
Obs: observed number of cancer cases; Exp: expected number of cancer cases based on cancer incidence in the compa-
rable Finnish population; SIR: standardized incidence ratio; CI: confidence interval; % of cancer: the percentage of patients 
diagnosed with a certain cancer during the follow-up.
a p < 0.001 
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risk for systemic tumors is not elevated after MoM THA (Case 
et al. 1996, Pandit et al. 2008, Ollivere et al. 2009, Langton 
et al. 2010). Our findings are in line with these studies. Sar-
hadi et al. (2015) studied DNA extracted from periprosthetic 
tissues of 20 MoM patients undergoing hip revision surgery 
because of ALTR. They found genetic alterations in 6 patients 
and a liposarcoma in 1 patient. 
In our previous short-term follow-up study of this same study 
population the risk of soft-tissue sarcomas was elevated in the 
MoM group compared twith the non-MoM-group (Mäkelä et 
al. 2014). Furthermore, in that study all sarcomas were diag-
nosed during the last 4 years of the follow-up, raising a con-
cern that during longer follow-up soft-tissue sarcomas might 
be overrepresented in the MoM cohort and that there might be 
a causative relationship between metal wear debris and soft-
tissue sarcomas. However, in the current study only 1 addi-
tional soft tissue sarcoma was observed during the additional 
follow-up years 2012–14, and the incidence was similar in 
the MoM patient population compared with the general Finn-
ish population and similar to the risk in the non-MoM group. 
Nonetheless, the overall number of sarcomas is small and we 
plan to report further follow-up. To our knowledge, there are 
no other studies reporting increased incidence of soft-tissue 
sarcomas in patients treated with metal-on-metal hip implants. 
Incidence of basalioma was higher in the MoM cohort than 
in the non-MoM cohort and also increased when compared 
with the Finnish population. A similar finding has previously 
been reported only with conventional total hip replacements 
(Brewster et al. 2013). The majority of the previous studies on 
MoM hip implants either exclude non-melanoma skin cancer 
or include basaliomas in the category of other skin cancers 
and the data on basalioma incidence in patients treated with 
MoM implants is limited (Visuri et al. 2006, Smith et al. 2012, 
Lalmohamed et al. 2013). Due to its benign nature, basalioma 
is traditionally not included in the official national cancer sta-
tistics. In Finland only the first basalioma for each person is 
recorded in the Finnish Cancer Registry (Pukkala et al. 2018). 
This may bias our results since patients treated with HRA 
are generally younger than patients treated with conventional 
THA, and it may therefore be more likely for them to be diag-
nosed with basalioma for the first time during our follow-up. 
We found that the incidence of skin melanoma was not ele-
vated in the MoM cohort compared with the general Finnish 
population. Earlier studies have found conflicting evidence 
concerning conventional non-MoM THAs’ association with 
melanoma incidence. Some studies have reported higher mel-
anoma incidence in patients treated with non-MoM implants 
than in the general population (Nyrén et al. 1995, Olsen et al. 
1999, Visuri et al. 2003, 2006) while others have found no dif-
ference (Visuri et al. 2010, Levasic et al. 2018). No increase 
in the risk of melanoma was found for patients treated with a 
MoM resurfacing device (Brewster et al. 2013). 
The study by Brewster et al. (2013) found an increased risk 
of multiple myeloma and other immunoproliferative neo-
plasms in THA patients during the first 4 years after arthro-
plasty. However, their study did not differentiate MoM bear-
ings from other types of bearings and the study also included 
patients with rheumatic conditions, which are known to 
increase the risk of immunoproliferative neoplasms (Isomäki 
et al. 1978). Our study found no excess risk of myeloma in the 
MoM hip implant patients.
We acknowledge that our study has several limitations. 
First, as with all registry-based studies there is a possibility 
of a selection bias. Registry-based studies have the advantage 
of reporting results from a large patient group and reporting 
so-called “real world data” but the disadvantage of possible 
confounding by indication (Freemantle et al. 2013). That is, 
the patients selected for THA or HRA may be for example 
healthier than the average population. Ideally this could be 
avoided by randomized controlled studies. Second, we did not 
have any blood metal ion measurements or imaging findings 
of the patients. It is theoretically possible that higher cancer 
risk might be associated with higher ion levels and our study 
is not able to detect such a subgroup. However, the findings 
of the meta-analysis by Christian et al. (2014) suggest that 
the concentrations and doses of Co/Cr required to induce a 
genotoxic or tumorigenic outcome are much higher than the 
systemic Co/Cr concentrations typically present in MoM 
hip implant patients. Third, even though our follow-up time 
now reaches the midterm point, genetic alterations might still 
happen or manifest later. In a recent meta-analysis Pijls et al. 
(2016) reported a higher risk of mortality in patients with MoM 
THA compared with patients with non-MoM THA when the 
follow-up exceeded 10 years. No difference was noted with 
shorter follow-up. Considering this we plan to report long-
term results from this same population.
In summary, patients treated with MoM hip implants had 
a comparable cancer risk to patients treated with non-MoM 
hip implants and the general Finnish population. They did not 
have increased risk for soft-tissue sarcoma or skin melanoma. 
Only the incidence for basalioma was increased in the MoM 
cohort compared with the non-MoM cohort and compared 
with the general population. 
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